Skip to content
Open access · CC-BY via OpenAlex

Translating the biology of aging into novel therapeutics for Alzheimer disease

Yuko Hara, Nicholas McKeehan, Howard M. Fillit

Neurology · 2018 · ▲ 122 citations

Abstract

Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer disease (AD), a progressive neurodegenerative disease with currently no therapies that prevent, slow, or halt disease progression. Like other chronic diseases of old age, the progressive pathology of AD begins decades before the onset of symptoms. Many decades of research in biological gerontology have revealed common processes that are relevant to understanding why the aging brain is vulnerable to AD. In this review, we frame the development of novel therapeutics for AD in the context of biological gerontology. The many therapies currently in development based on biological gerontology principles provide promise for the development of a new generation of therapeutics to prevent and treat AD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1212/wnl.0000000000006745
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Hara, Y., McKeehan, N., &amp; Fillit, H.M. (2018). Translating the biology of aging into novel therapeutics for Alzheimer disease. <em>Neurology</em>. https://doi.org/10.1212/wnl.0000000000006745
Vancouver
Hara Y, McKeehan N, Fillit HM. Translating the biology of aging into novel therapeutics for Alzheimer disease. Neurology. 2018. doi:10.1212/wnl.0000000000006745.
BibTeX
@article{yuko2018Transl, title = {Translating the biology of aging into novel therapeutics for Alzheimer disease}, author = {Yuko Hara and Nicholas McKeehan and Howard M. Fillit}, journal = {Neurology}, year = {2018}, doi = {10.1212/wnl.0000000000006745}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings